NCT00193687CompletedPhase 3
An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001)
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Solvay Pharmaceuticals
- Enrollment
- 986
Study Overview
Brief Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia. Extension to study S154.3.001.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •diagnosis of schizophrenia, understand nature of study, able to be managed in out-patient setting for long-term bifeprunox treatment
Exclusion Criteria
- •current primary diagnosis other than schizophrenia, suicide risk, diagnosis or history of substance abuse, uncontrolled hypertension
Investigators
Similar Trials
Completed
Phase 3
Bifeprunox in the Treatment of SchizophreniaSchizophreniaNCT00193713Solvay Pharmaceuticals
Terminated
Phase 3
Study Evaluating Bifeprunox in Patients With Schizophrenia.SchizophreniaNCT00366327Wyeth is now a wholly owned subsidiary of Pfizer400
Completed
Phase 2
Safety and Tolerability Study of Drug to Treat SchizophreniaSchizophreniaNCT00044005Sumitomo Pharma America, Inc.98
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaSchizophreniaNCT05184335Reviva Pharmaceuticals690
Terminated
Phase 3
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypePsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeNCT00160147Solvay Pharmaceuticals60